Integrative expression system for delivery of antibody fragments by lactobacilli by Martín, M. C. et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Mar. 2011, p. 2174–2179 Vol. 77, No. 6
0099-2240/11/$12.00 doi:10.1128/AEM.02690-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Integrative Expression System for Delivery of Antibody
Fragments by Lactobacilli†
M. Cruz Martín,1 Neha Pant,2 Victor Ladero,1 Go¨kc¸e Gu¨naydın,2 Kasper Krogh Andersen,2
Beatriz A´lvarez,2 Noelia Martínez,1 Miguel A. Alvarez,1
Lennart Hammarstro¨m,2 and Harold Marcotte2*
Instituto de Productos La´cteos de Asturias (IPLA, CSIC), 3300 Villaviciosa, Asturias, Spain,1 and Division of
Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at
Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden2
Received 16 November 2010/Accepted 11 January 2011
A series of expression cassettes which mediate secretion or surface display of antibody fragments was stably
integrated in the chromosome of Lactobacillus paracasei. L. paracasei producing surface-anchored variable
domain of llama heavy chain (VHH) (ARP1) directed against rotavirus showed efficient binding to rotavirus
and protection in the mouse model of rotavirus infection.
Lactobacilli are Gram-positive bacteria that are currently
used in food fermentation and preservation. Lactobacilli are
also normal constituents of the human microbiota and are
generally regarded as safe for humans (GRAS). There is an
increased interest in developing engineered lactobacilli as a
system for delivery of therapeutic and prophylactic biomol-
ecules (4, 19), and we have previously shown the potential of
lactobacilli to deliver single-chain variable fragment (scFv) and
variable domain of llama heavy chain (VHH) antibody frag-
ments to reduce oral and gastrointestinal infections in animal
models (7, 11, 15).
Stability and safety of the genetically engineered lactobacilli
used for medical application are of the utmost importance.
Various systems have previously been developed to stably in-
tegrate a heterologous gene into the chromosome, generating
food-grade expression systems devoid of antibiotic selection
genes (4). The recombinant proteins can be secreted into the
environment or displayed on the cell surface with covalent (7,
14, 19) or noncovalent (2, 17) binding.
In this article, we describe a chromosomally integrated ex-
pression system based on the aggregation-promoting factor
gene (apf) of Lactobacillus crispatus (9) to direct the expression
and secretion of antibody fragments combined with the site-
specific integration apparatus of the temperate bacteriophage
A2 to mediate chromosomal integration (12). The APF protein
has been identified in homofermentative lactobacilli, but pro-
teins with a homologous C-terminal part are also present in
heterofermentative lactobacilli and other Gram-positive bac-
teria (9, 17). This cell surface protein was originally hypothe-
sized to be involved in autoaggregation, but more recent re-
sults suggest rather an involvement in the maintenance of cell
shape (6, 18). The APF protein was selected as a vector mol-
ecule to deliver antibody fragments due to its high secretion
level in the supernatant and noncovalent cell wall anchoring
system (6, 9, 18).
Construction and selection of apf expression cassettes for
production of antibody fragments in Lactobacillus paracasei.
Our original publication described lactobacilli producing an
scFv antibody fragment against the SAI/II adhesin of Strepto-
coccus mutans, protecting against caries (7, 8). In order to
optimize the level of expression, the secretion, and the local-
ization of the antibody fragment, different translational fusions
were made between the gene encoding scFv and the apf gene
of L. crispatus M247 (see detailed materials and methods, Fig.
S1, and Table S1 in the supplemental material). The apf gene
of L. crispatus M247 encodes a 223-amino-acid protein con-
taining a signal peptide (33 amino acids), an N-terminal do-
main (75 amino acids), a central region rich in asparagine,
glutamine, threonine, and alanine (37 amino acids), and a
C-terminal domain (the last 78 amino acids) (GenBank acces-
sion no. AF492458) (9) (Fig. 1A). Using different fragments of
the apf gene and in some case the prtP gene region encoding
the last 231 amino acids of proteinase P for cell wall covalent
anchoring (7), a total of 11 expression cassettes were generated
(Fig. 1B). In each cassette, the antibody fragment was also
fused to an E tag for detection with an anti-E-tag antibody in
Western blotting and enzyme-linked immunosorbent assay
(ELISA). The pAF plasmid series (pAF100 to pAF1100) con-
taining the 11 expression cassettes was introduced into L. pa-
racasei (previously known as L. casei or L. zeae ATCC 393
pLZ15) (7, 15) by electroporation as previously described (7,
10), generating L. paracasei pAF100 to pAF1100. The most
important bacterial strains and plasmids used in this study are
listed in Table 1.
As shown by Western blot analysis of the supernatant
and cell extract of L. paracasei transformants (pAF100 to
pAF1100), fusion to different regions of the APF protein can
affect the level of secretion and the localization of the antibody
fragments (Fig. 1B). Cassettes lacking the middle region and
C-terminal domain of APF generate scFv in the supernatant
only (L. paracasei pAF100). The highest level of antibody frag-
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ments in the supernatant was obtained when the scFv antibody
fragment was fused to both the middle region and the C-ter-
minal part of APF (L. paracasei pAF400 and pAF500). Fur-
thermore, the highest level of scFv antibody in the cell extract
was detected when scFv was fused either to the middle region
and the C-terminal part of APF (L. paracasei pAF400 and
pAF500) or to the C-terminal domain of PrtP (L. paracasei
pAF900, pAF1000, and pAF1100).
It has previously been shown that the conserved APF car-
boxy termini might be involved, at least in part, in cell surface
attachment of the protein and that the APF could be stripped
from the surface of lactobacilli by LiCl treatment (18). The
Western blot results suggest that both the central and C-ter-
minal regions of the APF protein are important for cell wall
attachment since scFv could be significantly detected in the cell
extract only when fused to these two domains (pAF400 and
pAF500) (Fig. 1B). The central region might be either directly
involved in cell binding or indirectly involved by allowing the
correct folding of the C-terminal domain, needed for binding.
Treatment of the cell pellet of L. paracasei pAF400 with LiCl
was shown to remove 75% of the scFv fusion protein from the
cell pellet extract (Fig. 2Ai). In addition, a 55-kDa band, cor-
responding to the scFv fusion protein, was observed in the cell
extract of nontransformed L. paracasei preincubated for 2 h
with the culture supernatant of L. paracasei pAF400 (Fig.
2Aii). No band could be detected when L. paracasei had been
previously incubated with the supernatant of L. paracasei
pAF100 or nontransformed L. paracasei. These results confirm
that scFv can attach to the cell wall through the central and
C-terminal domains of APF. However, flow cytometry analysis
using a mouse anti-E-tag antibody and Cy-2-conjugated goat anti-
mouse immunoglobulin (5, 15) showed the presence of scFv
fragments on the cell surface of L. paracasei transformed with
the plasmids pAF900, pAF1000, and pAF1100 but not with the
plasmid pAF400 (Fig. 2B).
Three expression cassettes were selected for future applica-
tions based on the amount of scFv produced and the localiza-
tion of scFv. Expression cassettes producing fusion proteins
with short APF N termini were preferred, since it could oth-
erwise interfere with the folding of the antibody fragment. The
three selected plasmids were pAF100, generating secreted scFv
only, pAF400, generating both secreted and cell wall-attached
scFv, and pAF900, generating surface-anchored scFv.
Validation of expression cassettes by cloning of other anti-
body fragment-encoding genes. Since chromosomal integration
is cumbersome and we wanted to develop a universal expression
system for production of a broad range of antibody fragments, we
first verified that the selected cassettes contained in the plasmids
pAF100, pAF400, and pAF900 were suitable for expression of
other antibody fragments. scFv directed against human intercel-
FIG. 1. Production of scFv anti-SAI/II by L. paracasei transformed with plasmids containing different expression cassettes. (A) The APF protein
can be divided in three domains, N-terminal (N-ter), C-terminal (C-ter), and a central region which is rich in asparagine, glutamine, threonine,
and alanine. The promoter (P), the ribosomal binding sites (RBS), the signal peptide (sp), the translational stop codon (arrowhead), and the
transcription terminator (lollipop) are indicated. (B) scFv production was analyzed in cell extract (c) and supernatant (s) of L. paracasei
transformed with the plasmids pAF100 to pAF1100. The experiment was repeated twice, and all transformants were analyzed at the same time.
An equivalent of 125 l supernatant and extract from 1  108 cells was loaded in each well.
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lular adhesion molecule 1 (ICAM-1) (3) and VHH antibody frag-
ments against SAI/II (S36) (8) and rotavirus (ARP1 or VHH1)
(15) were selected since they were previously shown to be func-
tional and to have a therapeutic effect in vitro and in animal
models when produced by lactobacilli. Derivative pAF100,
pAF400, and pAF900 plasmids were constructed for the expres-
sion of scFv anti-ICAM-1 (pAF100-ICAM, pAF400-ICAM, and
pAF900 ICAM), S36 (pAF100-S36, pAF400-S36, and pAF900-
S36), and ARP1 (pAF100-ARP1, pAF400-ARP1, and pAF900-
ARP1) and introduced into L. paracasei.
Successful production of the antibody fragments by the mod-
ified L. paracasei bacteria was demonstrated using Western
blotting (see Fig. S2A in the supplemental material) and was
subsequently estimated by Western blot densitometry using
purified scFv fused to an E tag as a standard. The amount of
antibody fragments produced by L. paracasei transformed with
the pAF100 derivative plasmids was lower for scFv (anti-SAI/II
and anti-ICAM-1) (0.1 to 0.15 g/ml) than for VHH (ARP1
and S36) (0.5 to 0.7 g/ml). The largest amount of antibody
fragments was measured in the supernatant of L. paracasei
transformed with the pAF400 derivative plasmids (0.9 to 1
g/ml of scFv and 3 to 5 g/ml of VHH). The amounts of
antibody fragments present in the cell extract of L. paracasei
transformed with the pAF400 plasmids were similar for scFv
and VHH (103 molecules/bacterium), but a larger amount of
VHH than scFv molecules was observed in the cell extract of L.
paracasei transformed with pAF900 derivative plasmids (3 
103 to 6  103 versus 0.7  103 to 1  103 molecules/bacte-
rium). As observed above, flow cytometry analysis showed the
presence of scFv (anti-ICAM-1) and VHH (ARP1 and S36)
fragments on the cell surface of L. paracasei transformed with
the pAF900 plasmids (see Fig. S2B in the supplemental mate-
rial) but not with the pAF400 plasmids.
In ELISA, binding activity toward ICAM-1, SAI/II, and
rotavirus was observed in the supernatant of L. paracasei trans-
formed with the pAF100 and pAF400 derivative plasmids and
whole bacterial cells of L. paracasei transformed with the
pAF900 derivative plasmids (see Fig. S3 in the supplemental
material). However, no binding activity was observed using
whole L. paracasei transformed with the derivative pAF400
plasmids. The latter could be due to the E-tag being poorly
detected by the conjugated antibody when the fragment is
attached to the cell through the central and C-terminal domain
of APF as observed above. However, using BacLight Green-
stained bacteria in a spectrofluorometric microassay, we could
observe binding to antigen-coated plates by L. paracasei trans-
formed with pAF900 but not pAF400 plasmids (see Table S2).
Furthermore, binding to rotavirus by L. paracasei pAF900-
ARP1 but not pAF400-ARP1 was shown by flow cytometry
using rabbit anti-rotavirus VP6 and donkey anti-rabbit phyco-
erythrin (PE)-conjugated antibodies (15).
The antibody fragments attached to the surface of L. para-
casei via the central and C-terminal domain of APF may not
protrude sufficiently outside the bacterial surface to bind to
antigens or to be recognized by the anti-E tag in flow cytom-
etry. We have previously shown that the length of the anchor-
ing sequence is important to obtain a functional surface-dis-
played antibody (7). Insertion of a sequence between the
middle region of APF and the antibody fragment might thus be
necessary to elongate the fusion protein in order to improve
the display of antibody fragments.
Our results confirm the possibility of producing different
functional secreted and surface antibody fragments using the
described expression system. Although the central and C-ter-
minal part of APF does not allow the display of the antibody in
a functional way, it favors the secretion and/or stability of the
scFv antibodies in the supernatant. Furthermore, antibody
fragments bound to antigen could potentially reattach to the
Lactobacillus cells as suggested above (Fig. 2Aii). Most impor-
TABLE 1. Most important strains and plasmids used in this study
Strain or plasmid Relevant properties Reference or source
Strains
E. coli DH5
L. paracasei Previously considered a plasmid-free L. casei 393 15
L. paracasei pAF100 L. paracasei with pAF100 plasmid, secreted scFv anti-SAI/II This work
L. paracasei pAF400 L. paracasei with pAF400 plasmid, secreted and attached scFv anti-SAI/II This work
L. paracasei pAF900 L. paracasei with pAF900 plasmid, surface-anchored scFv anti-SAI/II This work
L. paracasei pAF900-ARP1 L. paracasei with pAF900-ARP1 plasmid, surface-anchored ARP1 This work
L. paracasei EM171 L. paracasei with integrated pAF400 cassette, secreted and attached scFv
anti-SAI/II
This work
L. paracasei EM181 L. paracasei with integrated pAF900 cassette, surface-anchored
scFv anti-SAI/II
This work
L. paracasei EM182 L. paracasei with integrated pAF100 cassette, secreted scFv anti-SAI/II This work
L. paracasei EM233 L. paracasei with integrated pAF900-ARP1 cassette, surface-anchored ARP1 This work
Plasmids
pIAV7 Broad-range vector, Err, lacZ, pWV01 replication origin 16
pAF100 to pAF1100 series pIAV7 with 11 expression cassettes This work
pEM76 Integrative vector containing six1, A2 int, attP, and six2 12
pEM94 Containing the -recombinase gene in order to delete the non-food-grade
DNA present in the integrated plasmids by site-specific recombination
13
pEM171 pEM76 with expression cassette of pAF400 This work
pEM181 pEM76 with expression cassette of pAF900 This work
pEM182 pEM76 with expression cassette of pAF100 This work
pEM233 pEM76 with expression cassette of pAF900-ARP1 This work
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tant, display of antibody fragments is efficiently obtained using
the PrtP anchor C-terminal domain.
Chromosomal integration of the gene encoding scFv anti-
SAI/II and ARP1. The pEM76 integration vector was previ-
ously described and contains the phage A2 integrase gene
(A2-int), which catalyzes the insertion of vector DNA contain-
ing the A2-attP site into an attB site present in the genome of
all lactic acid bacteria tested so far (1). The pEM76 vector was
used for integration of three selected cassettes fused to the
gene encoding scFv anti-SAI/II and one cassette mediating the
surface covalent anchoring of ARP1 into the chromosome
of L. paracasei. The expression cassettes from the plasmids
pAF100, pAF400, pAF900, and pAP900-ARP1 were cloned
into the integrative plasmid pEM76, generating pEM182,
pEM171, pEM181, and pEM233, respectively. The integrative
plasmids were introduced by electroporation into L. paracasei.
The resulting strains were subsequently electrotransformed
with pEM94, a replicative plasmid that carries the -recombi-
nase gene, in order to delete, by site-specific recombination,
the non-“food grade” DNA (antibiotic resistance gene, Esch-
erichia coli DNA) located between two six sites (13). After this
depuration step, the strains were cultured at 37°C to eliminate
pEM94 (which carries a temperature-sensitive origin of repli-
cation). The obtained strains were designated L. paracasei
EM171 (secreted and attached scFv), L. paracasei EM181 (co-
valently anchored scFv), L. paracasei EM182 (secreted scFv),
and L. paracasei EM233 (covalently anchored ARP1), respec-
tively. Each step (integration, depuration, and plasmid curing)
was confirmed by PCR analysis and Southern blotting (data
not shown).
When integrated in the chromosome, the amount of scFv in
the supernatant of L. paracasei EM182 (secreted scFv) and in
the cell extract of L. paracasei EM181 (surface-anchored scFv)
was about 10-fold lower than that when the corresponding
plasmid-based construct was used (approximately 10 ng/ml and
100 molecules/bacterium, respectively) as determined by West-
ern blot densitometry (see Fig. S4A in the supplemental ma-
terial). A 10-fold decrease in surface antibody display was also
observed in L. paracasei EM181 as shown by flow cytometry
(see Fig. S4B). However, the amount of scFv detected in the
supernatant and in the cell extract of EM171 (secreted and
attached scFv) was shown to be only 2-fold lower (approxi-
mately 500 ng/ml and 500 molecules/bacterium) than that in
the plasmid-based system. Using ELISA, binding activity to-
ward the SAI/II antigen was observed using the supernatant
and whole bacterial cells of integrated constructs but to a
reduced level in comparison to that with the equivalent plas-
mid constructs, which corresponds to the amount of antibody
produced (see Fig. S4C).
We have previously shown using a plasmid expression sys-
tem that lactobacilli producing surface-anchored ARP1 (but
not secreted ARP1) are protective in a mouse model of rota-
virus infection (15). Here we compared the activity of L. pa-
racasei producing surface-anchored ARP1 using the plasmid
(L. paracasei pAF900-ARP1) and integration system (L. para-
casei EM233) in vitro and in vivo. L. paracasei EM233 also
showed an intensity of the bands that was 10 times lower than
that for L. paracasei pAF900-ARP1, which corresponds to
approximately 600 molecules/bacterium (Fig. 3A). When the
display of the ARP1 fragment on the surface of bacteria was
evaluated by flow cytometry, the fluorescence intensity was
shown to be 6 times lower for L. paracasei EM233 than for the
corresponding plasmid construct, L. paracasei pAF900-ARP1
(Fig. 3B). The reason for the discrepancies between the two
methods is probably that only a fraction of the molecules
detected in the cell extract by Western blotting are displayed
on the surface.
The binding of whole cells of L. paracasei EM233 and L.
paracasei pAF900-ARP1 to rotavirus was shown to be similar
using flow cytometry (Fig. 3C) and immunofluorescence mi-
croscopy (see Fig. S5 in the supplemental material), while with
use of ELISA, whole cells of L. paracasei EM233 were shown
to bind to rotavirus particles at a level about 3 times lower than
that for the corresponding plasmid construct (Fig. 3D).
To evaluate construct stability, L. paracasei EM233 was also
grown for 50 generations and fluorescence intensity was mea-
sured at generations 10, 20, 30, 40, and 50. No difference was
observed in the fluorescence intensity between the different
generations, showing that the integrated gene is stable.
The prophylactic effect of modified L. paracasei was subse-
quently tested in the mouse pup model of rotavirus infection
FIG. 2. Evaluation of surface display of scFv anti-SAI/II in modi-
fied L. paracasei. (A) Demonstration of noncovalent attachment of
scFv to the surface of L. paracasei pAF400 by Western blotting. (i) The
bacterial pellet was treated with LiCl (5 M) to strip surface proteins,
and Western blotting of the cell extract was performed. (ii) Cell extract
from wild-type L. paracasei incubated with the culture supernatant of
wild-type L. paracasei (wt), L. paracasei pAF100, or L. paracasei
pAF400 to evaluate reattachment of scFv. (B) Flow cytometry analysis
showing the display of antibody fragments by L. paracasei transfor-
mants displaying surface-anchored scFv anti-SAI/II antibody frag-
ments.
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using single oral inoculums of 20 50% diarrhea-inducing doses
(DD50) of rhesus rotavirus (RRV) on day 0 (15). L. paracasei
pAF900-ARP1, L. paracasei EM233, and nontransformed L.
paracasei were orally administered once daily starting on day
1 and continuing until day 3, and the diarrhea score was
recorded daily until day 4. All mouse experiments were ap-
proved by the local ethics committee of the Karolinska Insti-
tutet at Karolinska University Hospital, Huddinge, Sweden. L.
paracasei pAF900-ARP1 and L. paracasei EM233 were shown
to reduce the duration and severity of diarrhea to similar levels
(Table 2).
The pEM76 delivery system was shown to create functional
and stable integration of expression cassettes mediating secre-
tion, secretion and attachment, and surface covalent anchoring
of antibody fragments in the model strain L. paracasei. The
reduction in antibody production is acceptable considering that
each bacterium contains one copy of the chromosome but
multiple copies of the plasmid (n 162) (16). Most important,
the level of ARP1 antibody fragment displayed in L. paracasei
EM233 was sufficient for the modified lactobacilli to reduce
infection when tested in an animal model of rotavirus infec-
tion. Conforming to previous data in our laboratory (15), our
present results showed that VHHs were produced at a higher
level when secreted in the supernatant or covalently anchored
on the surface than scFv antibody fragments. VHHs are
smaller and, since they are formed by a single polypeptide,
easier to produce in a recombinant form with an intact spatial
structure. They are without a doubt the antibodies of choice for
efficient production of antibody fragment using the integrated
system.
The integration and expression system described in this ar-
ticle may potentially apply to a range of Lactobacillus species.
In this study, we showed that the apf promoter originally from
L. crispatus was active in L. paracasei in which the apf gene is
absent. Furthermore, preliminary results also show a high ex-
pression in Lactobacillus rhamnosus GG (unpublished data).
The delivery system can be integrated in various lactic acid
bacteria since the integration machinery has some degree of
flexibility with regard to the sequence of the attB site (1). This
method eliminates the need to know the genome sequence
since the DNA always integrates at the attB site. Since the
temperate phage A2 is 44 kb in size, the integration of two or
more expression cassettes encoding antibodies of different
FIG. 3. (A) Production and binding activity of L. paracasei producing surface-anchored ARP1 using a plasmid-based (L. paracasei pAF900-
ARP1) and chromosomally integrated (L. paracasei EM233) expression system. (A) Production of ARP1, determined by Western blot analysis of
supernatant (s) and cell extract (c). An equivalent of 40 l supernatant and extract from 3.5  107 cells was loaded in each well. For L. paracasei
pAF900-ARP1, an arrowhead indicates the band corresponding to intact ARP1 fused to the C-terminal domain of PrtP. (B) Flow cytometry
analysis showing the display of ARP1 on the bacterial surface. (C) Flow cytometry analysis showing binding activity of modified L. paracasei for
rotavirus. (D) ELISA analysis showing binding activity of modified L. paracasei for rotavirus. Nontransformed L. paracasei and L. paracasei
pAF900-S36 were used as negative controls. The coefficient of variation between triplicates is less than 10%.
TABLE 2. Duration and severity of rotavirus-induced diarrhea in
the different treatment groups
Group No. ofmice
Durationa
(mean  SE, days)
Severityb
(mean  SE)
L. paracasei
pAF900-ARP1
7 1.00  0.22 1.00  0.22c
L. paracasei EM233 7 1.14  0.14 1.14  0.14c
L. paracasei 7 1.43  0.20 2.29  0.36
a The duration was defined as the total sum of days with diarrhea.
b No stool or normal stool was given a score of 0, loose stool a score of 1, and
watery diarrhea a score of 2. Severity was defined as the sum of diarrhea scores
for each pup during the course of the experiment (severity   diarrhea score
	day 1 
 day 2 
 day 3 
 day 4).
c Statistically significant difference from results for the L. paracasei group by
Kruskal-Wallis test (P  0.007) and Dunn test (P  0.05).
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specificities can probably be achieved. Taken together, this
work represents the first expression system that can be applied
to different lactobacilli and represents an important step for-
ward in the development of modified live lactobacilli produc-
ing antibody fragments for the food industry and for health
applications.
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